Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
Anne Auperin, Cecile Le Pechoux, Estelle Rolland et al. · Journal of Clinical Oncology · 2010
PURPOSE: The previous individual patient data meta-analyses of chemotherapy in locally advanced non-small-cell lung cancer (NSCLC) showed that adding sequential or concomitant chemotherapy to radiotherapy improved survival. The NSCLC Collaborative Group performed a meta-analysis of randomized trials directly comparing concomitant versus sequential radiochemotherapy. METHODS: Systematic searches for trials were undertaken, followed by central collection, checking, and reanalysis of updated individual patient data. Results from trials were combined using the stratified log-rank test to calculate pooled hazard ratios (HRs). The primary outcome was overall survival; secondary outcomes were progression-free survival, cumulative incidences of locoregional and distant progression, and acute toxicity. RESULTS: Of seven eligible trials, data from six trials were received (1,205 patients, 92% of all randomly assigned patients). Median follow-up was 6 years. There was a significant benefit of concomitant radiochemotherapy on overall survival (HR, 0.84; 95% CI, 0.74 to 0.95; P = .004), with an absolute benefit of 5.7% (from 18.1% to 23.8%) at 3 years and 4.5% at 5 years. For progression-free survival, the HR was 0.90 (95% CI, 0.79 to 1.01; P = .07). Concomitant treatment decreased locoregional progression (HR, 0.77; 95% CI, 0.62 to 0.95; P = .01); its effect was not different from that of sequential treatment on distant progression (HR, 1.04; 95% CI, 0.86 to 1.25; P = .69). Concomitant radiochemotherapy increased acute esophageal toxicity (grade 3-4) from 4% to 18% with a relative risk of 4.9 (95% CI, 3.1 to 7.8; P < .001). There was no significant difference regarding acute pulmonary toxicity. CONCLUSION: Concomitant radiochemotherapy, as compared with sequential radiochemotherapy, improved survival of patients with locally advanced NSCLC, primarily because of a better locoregional control, but at the cost of manageable increased acute esophageal toxicity.
Cited by 1,878 works. doi:10.1200/jco.2009.26.2543 Open-access PDF
Authors
- Anne Auperin
- Cecile Le Pechoux
- Estelle Rolland
- Walter John Curran
- Kiyoyuki Furuse
- P. Fournel
- José S.A. Belderbos
- Gerald H. Clamon
- H Cüneyt Ulutin
- Rebecca Paulus
- Takeharu Yamanaka
- Marie‐Cécile Bozonnat
- A. L. J. Uitterhoeve
- Xiaofei Wang
- Lesley A. Stewart
- Rodrigo Arriagada
- Sarah Burdett
- Jean‐Pierre Pignon
References
- Quantifying heterogeneity in a meta‐analysis
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
- Cancer incidence, mortality and prevalence worldwide
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)
- Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
- A note on quantifying follow-up in studies of failure time
- Systemic Treatment of Early Breast Cancer by Hormonal, Cytotoxic, or Immune Therapy:133 Randomised Trials involoving 31 000 Recurrences and 24 000 Deaths Among 75 000 Women (Summary)
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients